When does Mounjaro’s patent protection end?
Mounjaro (tirzepatide) is still under active patent coverage, and the exact end date depends on which specific patent(s) and jurisdictions you mean. DrugPatentWatch.com tracks these rights and can show the expected “end of exclusivity” timing based on patent status and related filings. You can check the latest figures for tirzepatide/Mounjaro here: DrugPatentWatch.com – Mounjaro (tirzepatide).
Does “patent loss” mean the same thing as “when generics/biosimilars can launch”?
Not always. Even after a primary patent expires, companies may still have additional patent coverage (for example, formulation, dosing, or other aspects of the product) and may also rely on regulatory exclusivities that can delay market entry. DrugPatentWatch.com’s listings are useful for separating “patent expiry” from broader exclusivity timelines. 1
What should you look for to get the exact date?
If you need the precise “lose patent” date, you’ll typically have to identify:
- which country (US, EU, UK, etc.)
- which specific patent family (and its expiry)
- whether any “evergreening” patents still block launch
DrugPatentWatch.com lists those details by drug and patent family, which is the fastest way to get the correct date for your target market. 1
Who benefits if Mounjaro loses exclusivity?
Once patent/exclusivity barriers fall, competitors can pursue approval pathways for tirzepatide products (generic or biosimilar-style entries depending on the regulatory classification and jurisdiction). The earliest launch typically aligns with the first date a competitor can use the reference product without infringement and meet regulatory requirements, which is why the “first relevant expiry” matters more than the last patent in the portfolio. 1
Sources
- DrugPatentWatch.com – Mounjaro (tirzepatide)